NEW YORK — Levi & Korsinsky, LLP has alerted investors to a pending securities class action lawsuit against Boston Scientific Corporation (NYSE: BSX), alleging the company misrepresented growth trends in its U.S. electrophysiology (EP) business.
The lawsuit seeks to recover damages for investors who purchased Boston Scientific securities between July 23, 2025 and February 3, 2026. Investors have until May 4, 2026 to seek appointment as lead plaintiff in the case.
According to the complaint, Boston Scientific’s stock dropped $16.12 per share — or 17.6% — on February 4, 2026, falling from $91.62 to $75.50 in a single day following disclosures that raised concerns about the sustainability of EP procedure growth.
The case centers on allegations that company executives overstated the strength and trajectory of the EP market while downplaying slowing procedure volumes and increasing competitive pressure. The lawsuit contends that Boston Scientific continued to promote its EP segment as a high-growth leader despite internal awareness of emerging headwinds.
The filing highlights several claims, including that the company reported 94% EP sales growth in the second quarter of 2025 following the initial U.S. launch of its FARAPULSE system, a comparison that allegedly inflated perceived performance. Management later reported 63% growth in the third quarter, which the lawsuit characterizes as a deceleration rather than continued acceleration.
Plaintiffs also allege that Boston Scientific projected long-term EP market growth of 15% and anticipated pulsed field ablation (PFA) adoption to rise from 50% to 80% by 2028, while suggesting that catheter labs were performing more than 30% additional procedures following the FARAPULSE rollout. The complaint argues these projections overstated capacity and demand.
Additionally, the lawsuit claims the company positioned its FARAFLEX technology as dominating the complex arrhythmia market while portraying competitors as lagging, despite intensifying competition.
The complaint further alleges that Boston Scientific cited expansion of ambulatory surgery centers and new catheterization labs as growth drivers, while failing to adequately disclose constraints tied to reimbursement structures and the limited pace of new facility openings. The filing notes that reimbursement for certain procedures had only been established in October 2024, and that the company itself described these procedures as “still a very new phenomenon.”
“The complaint raises serious questions about whether investors received accurate information regarding the sustainability of procedure volume growth in the U.S. EP market, particularly as competitive entrants gained traction and reimbursement dynamics remained uncertain,” said Joseph E. Levi, Esq.
The case remains pending, and the allegations have not been proven in court.
